Northwest Biotherapeutics (NWBO) FCF Margin (2010 - 2026)
Northwest Biotherapeutics' (NWBO) quarterly FCF Margin came in at 2558.3% in Q1 2026, down 2203.0% year-on-year from 121.65% in Q1 2025, and down 9.72% quarter-over-quarter from 2331.7% in Q4 2025.
Northwest Biotherapeutics (NWBO) FCF Margin (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' FCF Margin history runs 17 years deep, the most recent figure standing at 2558.3% for Q1 2026.
- On a quarterly basis, FCF Margin fell 2203.0% year-over-year to 2558.3% in Q1 2026; TTM through Mar 2026 was 3299.53%, a 42735.0% increase from a year earlier, with the FY2025 full-year figure at 3357.55%, up 84151.0% from the prior year.
- FCF Margin slipped to 2558.3% in Q1 2026 per NWBO's latest filing, from 2331.7% in the prior quarter.
- Across five years, FCF Margin topped out at 1428.64% in Q1 2023 and bottomed at 8770.13% in Q4 2024.
- The 5-year median for FCF Margin is 3278.04% (2024), against an average of 4124.76%.
- Across the five-year window, FCF Margin tumbled 518568 bps in 2022 and surged 643843 bps in 2025, its largest moves.
- Year by year, FCF Margin stood at 1844.05% in 2022, then slumped by 112 bps to 3904.72% in 2023, then plunged by 125 bps to 8770.13% in 2024, then surged by 73 bps to 2331.7% in 2025, then dropped by 10 bps to 2558.3% in 2026.
- Per Business Quant, the three latest NWBO FCF Margin figures stand at 2558.3% (Q1 2026), 2331.7% (Q4 2025), and 7047.5% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 4.17% |
| 10 | Northwest Biotherapeutics | 275.76 Mn | 273.98 Mn | - | -2,558.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,558.30% |
| Dec 31, 2025 | -2,331.70% |
| Sep 30, 2025 | -7,047.50% |
| Jun 30, 2025 | -5,337.40% |
| Mar 31, 2025 | -2,536.27% |
| Dec 31, 2024 | -8,770.13% |
| Sep 30, 2024 | -2,355.46% |
| Jun 30, 2024 | -3,278.04% |
| Mar 31, 2024 | -4,452.46% |
| Dec 31, 2023 | -3,904.72% |
| Sep 30, 2023 | -3,535.96% |
| Jun 30, 2023 | -6,353.23% |
| Mar 31, 2023 | -1,428.64% |
| Dec 31, 2022 | -1,844.05% |
| Sep 30, 2022 | -7,958.25% |
| Jun 30, 2022 | -3,196.86% |
| Mar 31, 2022 | -3,232.01% |
| Sep 30, 2021 | -2,772.57% |
| Jun 30, 2021 | -1,994.95% |
| Mar 31, 2021 | -5,653.56% |